GETUG-AFU 15
•Download as PPTX, PDF•
0 likes•1,077 views
The GETUG 15 trial tested whether adding docetaxel chemotherapy to androgen deprivation therapy (ADT) would prolong overall survival in 385 men with hormone-sensitive metastatic prostate cancer. The trial found that adding docetaxel to ADT significantly prolonged both progression-free survival and clinical progression-free survival compared to ADT alone, with median progression-free survival of 23 months versus 13 months and median clinical progression-free survival of 23 months versus 15 months. However, the trial found no significant difference in overall survival between the two groups, with median overall survival of 59 months for those receiving docetaxel plus ADT versus 54 months for ADT alone.
Report
Share
Report
Share
Recommended
Metastatic Castration Resistant Prostate Cancer(mCRPC)
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer that has spread to other organs and continues to progress despite hormone therapy. Current treatments aim to reduce testosterone levels, disrupt microtubules during cell division, activate the immune system, or use radiopharmaceuticals, but all have limitations like toxicity or development of resistance. Researchers are exploring new targets and combinations of drugs to block cancer progression and prolong survival for men with mCRPC, which remains largely incurable.
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
In recent years, researchers have been looking into using a class of drugs called PARP inhibitors to prevent the progression and recurrence of ovarian cancer. Dr. Kathleen Moore of Stephenson Cancer Center, Principal Investigator of the SOLO-1 trial, explains how the results of this trial may affect ovarian cancer patients and where research on ovarian cancer treatment is headed next.
Advances in management of hormone sensitive prostate cancer
This presentation details the advances in management of metastatic hormone sensitive prostate cancer.
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
On May 22, 2013, SHARE presented "Recurrent Ovarian Cancer: Now What?" The program featured Dr. Ginger Gardner and Dr. Paul Sabbatini of Memorial Sloan-Kettering Cancer Center discussing treatment strategies, as well as new approaches and agents, for managing an ovarian cancer recurrence. Listen to the audio here http://www.sharecancersupport.org/sabbatini.
The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment.
New in management of hormone sensitive prostate cancer
#prostatecancer #prostate #cancer #prostatecancerinindia #prostatecancerindelhi #prostatecancertreatment #maxhospital #maxhospitaldelhi #dralokgupta #cancerspecialist #cancerdoctorindelhi #alokgupta
#immunotherapy
Recurrent ovarian cancer
Management Of Recurrent Ovarian Ca (ROC)
The document discusses the management of recurrent ovarian cancer. It provides details on the incidence and patterns of recurrence for ovarian cancer. For patients with platinum-sensitive recurrent ovarian cancer, the standard treatment is second line chemotherapy. Several chemotherapy regimens are discussed including carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin. For partially platinum-sensitive recurrent ovarian cancer, the OVA-301 trial showed improved overall survival with the combination of carboplatin and pegylated liposomal doxorubicin compared to carboplatin alone. Management of recurrent ovarian cancer aims to prolong survival, delay progression,
Transforming Treatment in Ovarian Cancer
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
Strategies for Managing Recurrent Ovarian Cancer
When ovarian cancer returns, it's not uncommon to experience a range of emotions and feel overwhelmed. But it's important to remember that recurrent ovarian cancer can often be successfully treated. Dr. Shannon N. Westin, gynecologic oncologist and clinical investigator at MD Anderson Cancer Center, goes over the latest treatment options for recurrent disease.
Recommended
Metastatic Castration Resistant Prostate Cancer(mCRPC)
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer that has spread to other organs and continues to progress despite hormone therapy. Current treatments aim to reduce testosterone levels, disrupt microtubules during cell division, activate the immune system, or use radiopharmaceuticals, but all have limitations like toxicity or development of resistance. Researchers are exploring new targets and combinations of drugs to block cancer progression and prolong survival for men with mCRPC, which remains largely incurable.
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
In recent years, researchers have been looking into using a class of drugs called PARP inhibitors to prevent the progression and recurrence of ovarian cancer. Dr. Kathleen Moore of Stephenson Cancer Center, Principal Investigator of the SOLO-1 trial, explains how the results of this trial may affect ovarian cancer patients and where research on ovarian cancer treatment is headed next.
Advances in management of hormone sensitive prostate cancer
This presentation details the advances in management of metastatic hormone sensitive prostate cancer.
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
On May 22, 2013, SHARE presented "Recurrent Ovarian Cancer: Now What?" The program featured Dr. Ginger Gardner and Dr. Paul Sabbatini of Memorial Sloan-Kettering Cancer Center discussing treatment strategies, as well as new approaches and agents, for managing an ovarian cancer recurrence. Listen to the audio here http://www.sharecancersupport.org/sabbatini.
The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment.
New in management of hormone sensitive prostate cancer
#prostatecancer #prostate #cancer #prostatecancerinindia #prostatecancerindelhi #prostatecancertreatment #maxhospital #maxhospitaldelhi #dralokgupta #cancerspecialist #cancerdoctorindelhi #alokgupta
#immunotherapy
Recurrent ovarian cancer
Management Of Recurrent Ovarian Ca (ROC)
The document discusses the management of recurrent ovarian cancer. It provides details on the incidence and patterns of recurrence for ovarian cancer. For patients with platinum-sensitive recurrent ovarian cancer, the standard treatment is second line chemotherapy. Several chemotherapy regimens are discussed including carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin. For partially platinum-sensitive recurrent ovarian cancer, the OVA-301 trial showed improved overall survival with the combination of carboplatin and pegylated liposomal doxorubicin compared to carboplatin alone. Management of recurrent ovarian cancer aims to prolong survival, delay progression,
Transforming Treatment in Ovarian Cancer
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
Strategies for Managing Recurrent Ovarian Cancer
When ovarian cancer returns, it's not uncommon to experience a range of emotions and feel overwhelmed. But it's important to remember that recurrent ovarian cancer can often be successfully treated. Dr. Shannon N. Westin, gynecologic oncologist and clinical investigator at MD Anderson Cancer Center, goes over the latest treatment options for recurrent disease.
Castrate Resistant Prostate Cancer
This document summarizes treatment approaches for metastatic castration-resistant prostate cancer (mCRPC). It discusses definitions of CRPC and mechanisms of resistance. For mCRPC patients with PSADT >10 months and no symptoms, secondary hormonal therapies are recommended, while those with PSADT <10 months receive second-generation antiandrogens. Docetaxel remains first-line for symptomatic mCRPC, while abiraterone, enzalutamide, radium-223, and sipuleucel-T are also options. Detection of AR-V7 in circulating tumor cells may help determine if taxanes or AR-targeted therapies are most suitable. Ongoing treatment, monitoring of
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
Landmark chemotherapy trials in advanced ovarian cancer established platinum-based combinations as the standard of care. GOG 47 (1986) showed cisplatin improves response rates and progression-free survival compared to cyclophosphamide alone. GOG 111 (1996) found the combination of paclitaxel and cisplatin improved progression-free and overall survival over cyclophosphamide and cisplatin. Subsequent trials determined carboplatin as an effective alternative to cisplatin, with fewer side effects.
Update on clinical trials in cervical cancer
Congreso de cáncer de cérvix, organizado por René Pareja, Lina Trujillo y Claudia Calle, Hotel Interecontinental Medellín, Junio 22-24, 2017
Landmark trials in Ovarian Cancer
Describes about the Evolution in the treatment of Ovarian cancer with evidence based discussion of landmark trials
Colon cancer chemotherapy trials
This document discusses chemotherapy trials and regimens for colon cancer. It summarizes several landmark trials that established the benefit of 5-FU-based adjuvant chemotherapy for stage III colon cancer. The MOSAIC, NSABP C-07 and NO16968 trials showed that adding oxaliplatin to 5-FU improves disease-free survival for stage III disease. For stage II, the benefit of oxaliplatin is unclear. The document also discusses staging, risk factors, treatment guidelines, neoadjuvant therapy and radiation therapy options for colon cancer.
Recent advances in targeted therapy for metastatic lung cancer
This document discusses recent advances in targeted therapy for metastatic lung cancer. It summarizes key findings from several clinical trials evaluating third-generation EGFR TKIs like osimertinib for patients with EGFR mutation-positive NSCLC. The document highlights that osimertinib provides significantly longer progression-free survival compared to earlier generation EGFR TKIs, with a median PFS of 18.9 months versus 10.2 months. Osimertinib also demonstrated a higher objective response rate and longer duration of response. Benefits were consistent across patient subgroups.
Recurrent Epithelial Ovarian Cancer
Describes platinum sensitivity and Evidence based treatment options for Recurrent Epithelial Ovarian Cancers
Anti-HER2 Therapies in Breast Cancer
The document discusses neoadjuvant and adjuvant therapies for HER2-positive breast cancer. It summarizes several clinical trials evaluating combinations of trastuzumab, pertuzumab, docetaxel, and other chemotherapies in the neoadjuvant and adjuvant settings. Combinations including dual HER2 blockade with trastuzumab and pertuzumab were found to significantly improve pathological complete response rates compared to other regimens. Ongoing studies continue exploring new targeted agents and combinations to further improve outcomes for patients with high-risk HER2-positive breast cancer.
CRPC management
This document summarizes current dilemmas in early management of castration-resistant prostate cancer (CRPC). It discusses definitions of CRPC and its natural history progression. Factors contributing to inevitable disease progression despite androgen deprivation therapy include alternate androgen biosynthesis, androgen receptor abnormalities, proliferation cascades, and changes in histology. Genetic alterations in prostate cancer like BRCA mutations are also reviewed. Recent positive clinical trial results establishing new standards of care for both chemo-naïve and post-docetaxel CRPC are highlighted. Optimal sequencing of available therapies remains an area of ongoing research due to heterogeneity in patient populations and lack of head-to-head trials.
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
This document discusses the management of early HER2+ breast cancer. It defines early breast cancer and describes the HER2+ subtype, which accounts for around 25% of cases. For early HER2+ breast cancer, neoadjuvant chemotherapy plus trastuzumab improves pathological complete response rates and long-term outcomes compared to chemotherapy alone. Multiple trials demonstrate the benefit of adding pertuzumab or T-DM1 to neoadjuvant regimens. Post-neoadjuvant surgery may require close evaluation of margins due to heterogeneous response.
Prostate cancer updates 2021
This document discusses locally advanced high risk prostate cancer and evolving treatment options. It provides an overview of risk stratification, guidelines for biopsy from the European Association of Urology, options for imaging with multiparametric MRI, and options for treatment including radical prostatectomy, radiation therapy, and hormonal therapy. New advances in radiation therapy include stereotactic body radiation therapy and hypofractionated regimens. Advances in hormonal therapy include gonadotropin-releasing hormone antagonists and oral options like relugolix. Neoadjuvant docetaxel chemotherapy is also discussed for high risk localized disease.
Update on Management of Triple Negative Breast Cancer
This document provides an update on the management of triple negative breast cancer from Dr. Banu Arun at MD Anderson Cancer Center. It discusses that triple negative breast cancer is a heterogeneous disease comprised of several molecular subtypes with different characteristics and potential treatment targets. Clinical trials exploring chemotherapy regimens, platinum agents, PARP inhibitors, anti-angiogenic drugs, and immunotherapies are summarized. Ongoing research aims to better define the subtypes in order to personalize treatment for triple negative breast cancer patients.
Induction chemotherapy for locally advanced head and neck cancers
The document discusses studies on induction chemotherapy for head and neck squamous cell carcinomas. It summarizes that two large randomized controlled trials, TAX 323 and TAX 324, found that induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) improved progression-free survival and overall survival compared to induction chemotherapy with cisplatin and fluorouracil alone. A larger study called GSTCC also found improved overall survival for patients receiving induction TPF before concurrent chemoradiotherapy compared to concurrent chemotherapy alone.
PARP inhibitor in Ca Ovary
Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. It is causing a paradigm shift in the first-line treatment of patients with advanced ovarian cancer
Changing landscape in the treatment of advanced prostate cancer
This presentation describes how the treatment of stage 4 prostate cancer has improved over last 100 years. This was presented at URO ONCOLOGY UPDATE meeting of Delhi Urological Society on 18th March 2017
MANAGEMENT OF LUMINAL BREAST CANCER.pptx
This document discusses the management of luminal breast cancers. It covers several topics:
1) The different breast cancer subtypes, including luminal A and B cancers, which make up 50-60% and 15-20% of cases respectively. Luminal A has a better prognosis while luminal B is more aggressive.
2) The need for molecular signatures to better classify cancers and predict outcomes. Trials have shown certain gene expression profiles can determine if chemotherapy is needed.
3) Guidelines for adjuvant systemic therapies for luminal cancers, including chemotherapy, endocrine therapy, radiation, and duration of treatment. Trials support extended endocrine therapy to lower recurrence risk.
4) Neoadjuvant endocrine therapy
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Fight Colorectal Cancer’s Medical Advisory Board Member, Axel Grothey, MD, focused this webinar to stage III colon cancer patients. Dr. Grothey, medical oncologist at Mayo Clinic, will spend the hour discussing current treatment options and exciting new research that pertains to stage III colon cancer patients.
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and locally advanced breast cancer By Prof. Dr.Syed Ijaz Hussain Shah (Oncologist)
Management of crpc
It highlights the the treatment options currently available for the management of castrate resistant prostate cancer.
Soft & text trial- an overview
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Farmacodermias
En esta presentación hemos recabado información relevante acerca de las farmacodermias más frecuentes y un poco de las menos frecuentes. Es un tema bastante extenso, pero importante.
Efecto a largo plazo de reducción de sal sobre Presión Arterial
Este documento presenta los resultados de un metaanálisis sobre los efectos de reducir moderadamente la ingesta de sal en la presión arterial. El estudio encontró que una reducción promedio de 4.4 g/día en la ingesta de sal a largo plazo causa una disminución significativa de la presión arterial en personas hipertensas y normotensas, con una reducción promedio de 5/3 mmHg y 2/1 mmHg respectivamente. Además, los análisis de subgrupos mostraron reducciones significativas de la presión arterial sistólica
More Related Content
What's hot
Castrate Resistant Prostate Cancer
This document summarizes treatment approaches for metastatic castration-resistant prostate cancer (mCRPC). It discusses definitions of CRPC and mechanisms of resistance. For mCRPC patients with PSADT >10 months and no symptoms, secondary hormonal therapies are recommended, while those with PSADT <10 months receive second-generation antiandrogens. Docetaxel remains first-line for symptomatic mCRPC, while abiraterone, enzalutamide, radium-223, and sipuleucel-T are also options. Detection of AR-V7 in circulating tumor cells may help determine if taxanes or AR-targeted therapies are most suitable. Ongoing treatment, monitoring of
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
Landmark chemotherapy trials in advanced ovarian cancer established platinum-based combinations as the standard of care. GOG 47 (1986) showed cisplatin improves response rates and progression-free survival compared to cyclophosphamide alone. GOG 111 (1996) found the combination of paclitaxel and cisplatin improved progression-free and overall survival over cyclophosphamide and cisplatin. Subsequent trials determined carboplatin as an effective alternative to cisplatin, with fewer side effects.
Update on clinical trials in cervical cancer
Congreso de cáncer de cérvix, organizado por René Pareja, Lina Trujillo y Claudia Calle, Hotel Interecontinental Medellín, Junio 22-24, 2017
Landmark trials in Ovarian Cancer
Describes about the Evolution in the treatment of Ovarian cancer with evidence based discussion of landmark trials
Colon cancer chemotherapy trials
This document discusses chemotherapy trials and regimens for colon cancer. It summarizes several landmark trials that established the benefit of 5-FU-based adjuvant chemotherapy for stage III colon cancer. The MOSAIC, NSABP C-07 and NO16968 trials showed that adding oxaliplatin to 5-FU improves disease-free survival for stage III disease. For stage II, the benefit of oxaliplatin is unclear. The document also discusses staging, risk factors, treatment guidelines, neoadjuvant therapy and radiation therapy options for colon cancer.
Recent advances in targeted therapy for metastatic lung cancer
This document discusses recent advances in targeted therapy for metastatic lung cancer. It summarizes key findings from several clinical trials evaluating third-generation EGFR TKIs like osimertinib for patients with EGFR mutation-positive NSCLC. The document highlights that osimertinib provides significantly longer progression-free survival compared to earlier generation EGFR TKIs, with a median PFS of 18.9 months versus 10.2 months. Osimertinib also demonstrated a higher objective response rate and longer duration of response. Benefits were consistent across patient subgroups.
Recurrent Epithelial Ovarian Cancer
Describes platinum sensitivity and Evidence based treatment options for Recurrent Epithelial Ovarian Cancers
Anti-HER2 Therapies in Breast Cancer
The document discusses neoadjuvant and adjuvant therapies for HER2-positive breast cancer. It summarizes several clinical trials evaluating combinations of trastuzumab, pertuzumab, docetaxel, and other chemotherapies in the neoadjuvant and adjuvant settings. Combinations including dual HER2 blockade with trastuzumab and pertuzumab were found to significantly improve pathological complete response rates compared to other regimens. Ongoing studies continue exploring new targeted agents and combinations to further improve outcomes for patients with high-risk HER2-positive breast cancer.
CRPC management
This document summarizes current dilemmas in early management of castration-resistant prostate cancer (CRPC). It discusses definitions of CRPC and its natural history progression. Factors contributing to inevitable disease progression despite androgen deprivation therapy include alternate androgen biosynthesis, androgen receptor abnormalities, proliferation cascades, and changes in histology. Genetic alterations in prostate cancer like BRCA mutations are also reviewed. Recent positive clinical trial results establishing new standards of care for both chemo-naïve and post-docetaxel CRPC are highlighted. Optimal sequencing of available therapies remains an area of ongoing research due to heterogeneity in patient populations and lack of head-to-head trials.
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
This document discusses the management of early HER2+ breast cancer. It defines early breast cancer and describes the HER2+ subtype, which accounts for around 25% of cases. For early HER2+ breast cancer, neoadjuvant chemotherapy plus trastuzumab improves pathological complete response rates and long-term outcomes compared to chemotherapy alone. Multiple trials demonstrate the benefit of adding pertuzumab or T-DM1 to neoadjuvant regimens. Post-neoadjuvant surgery may require close evaluation of margins due to heterogeneous response.
Prostate cancer updates 2021
This document discusses locally advanced high risk prostate cancer and evolving treatment options. It provides an overview of risk stratification, guidelines for biopsy from the European Association of Urology, options for imaging with multiparametric MRI, and options for treatment including radical prostatectomy, radiation therapy, and hormonal therapy. New advances in radiation therapy include stereotactic body radiation therapy and hypofractionated regimens. Advances in hormonal therapy include gonadotropin-releasing hormone antagonists and oral options like relugolix. Neoadjuvant docetaxel chemotherapy is also discussed for high risk localized disease.
Update on Management of Triple Negative Breast Cancer
This document provides an update on the management of triple negative breast cancer from Dr. Banu Arun at MD Anderson Cancer Center. It discusses that triple negative breast cancer is a heterogeneous disease comprised of several molecular subtypes with different characteristics and potential treatment targets. Clinical trials exploring chemotherapy regimens, platinum agents, PARP inhibitors, anti-angiogenic drugs, and immunotherapies are summarized. Ongoing research aims to better define the subtypes in order to personalize treatment for triple negative breast cancer patients.
Induction chemotherapy for locally advanced head and neck cancers
The document discusses studies on induction chemotherapy for head and neck squamous cell carcinomas. It summarizes that two large randomized controlled trials, TAX 323 and TAX 324, found that induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) improved progression-free survival and overall survival compared to induction chemotherapy with cisplatin and fluorouracil alone. A larger study called GSTCC also found improved overall survival for patients receiving induction TPF before concurrent chemoradiotherapy compared to concurrent chemotherapy alone.
PARP inhibitor in Ca Ovary
Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. It is causing a paradigm shift in the first-line treatment of patients with advanced ovarian cancer
Changing landscape in the treatment of advanced prostate cancer
This presentation describes how the treatment of stage 4 prostate cancer has improved over last 100 years. This was presented at URO ONCOLOGY UPDATE meeting of Delhi Urological Society on 18th March 2017
MANAGEMENT OF LUMINAL BREAST CANCER.pptx
This document discusses the management of luminal breast cancers. It covers several topics:
1) The different breast cancer subtypes, including luminal A and B cancers, which make up 50-60% and 15-20% of cases respectively. Luminal A has a better prognosis while luminal B is more aggressive.
2) The need for molecular signatures to better classify cancers and predict outcomes. Trials have shown certain gene expression profiles can determine if chemotherapy is needed.
3) Guidelines for adjuvant systemic therapies for luminal cancers, including chemotherapy, endocrine therapy, radiation, and duration of treatment. Trials support extended endocrine therapy to lower recurrence risk.
4) Neoadjuvant endocrine therapy
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Fight Colorectal Cancer’s Medical Advisory Board Member, Axel Grothey, MD, focused this webinar to stage III colon cancer patients. Dr. Grothey, medical oncologist at Mayo Clinic, will spend the hour discussing current treatment options and exciting new research that pertains to stage III colon cancer patients.
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and locally advanced breast cancer By Prof. Dr.Syed Ijaz Hussain Shah (Oncologist)
Management of crpc
It highlights the the treatment options currently available for the management of castrate resistant prostate cancer.
Soft & text trial- an overview
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
What's hot (20)
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
Recent advances in targeted therapy for metastatic lung cancer
Recent advances in targeted therapy for metastatic lung cancer
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
Induction chemotherapy for locally advanced head and neck cancers
Induction chemotherapy for locally advanced head and neck cancers
Changing landscape in the treatment of advanced prostate cancer
Changing landscape in the treatment of advanced prostate cancer
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancer
Viewers also liked
Farmacodermias
En esta presentación hemos recabado información relevante acerca de las farmacodermias más frecuentes y un poco de las menos frecuentes. Es un tema bastante extenso, pero importante.
Efecto a largo plazo de reducción de sal sobre Presión Arterial
Este documento presenta los resultados de un metaanálisis sobre los efectos de reducir moderadamente la ingesta de sal en la presión arterial. El estudio encontró que una reducción promedio de 4.4 g/día en la ingesta de sal a largo plazo causa una disminución significativa de la presión arterial en personas hipertensas y normotensas, con una reducción promedio de 5/3 mmHg y 2/1 mmHg respectivamente. Además, los análisis de subgrupos mostraron reducciones significativas de la presión arterial sistólica
Cpncp 2ªl
1. Se presenta el caso de una mujer de 58 años con adenocarcinoma pulmonar no microcítico metastásico que progresó a primera línea de tratamiento con quimioterapia basada en platino. 2. Las opciones de tratamiento en segunda línea incluyen docetaxel, pemetrexed (para histología no escamosa), erlotinib, nintedanib (para adenocarcinoma), ramucirumab y las inmunoterapias nivolumab y pembrolizumab. 3. El comité evaluará el caso para considerar inmunoterapia en segunda
Micosis fungoide
Este documento describe la micosis fungoide, un tipo de linfoma cutáneo primario de células T. Comienza con una breve introducción sobre los linfomas cutáneos primarios y continúa describiendo las características clínicas, histopatológicas y de presentación de la micosis fungoide, incluidas sus variantes. También cubre su epidemiología, etiología, cuadro clínico y estadificación. Finalmente, discute brevemente el síndrome de Sézary, una variante agresiva de la micosis
Enfrentamiento Shock Séptico
Este documento describe las recomendaciones actuales para el manejo inicial del shock séptico, incluyendo la detección temprana de hipoperfusión, reanimación agresiva dirigida a normalizar los parámetros de perfusión en las primeras horas utilizando protocolos como la terapia temprana guiada por objetivos, y el uso de fluidos como principal herramienta terapéutica guiada por metas de perfusión como el lactato o saturación venosa central.
Cancer Prostata Resistente Castración
Este documento resume el tratamiento del cáncer de próstata resistente a la castración (CRPC). Define el CRPC y describe los mecanismos de resistencia a la castración. Detalla los tratamientos disponibles como la quimioterapia citotóxica, abiraterona, enzalutamida, radium-223 y sipuleucel-T. También cubre la hormonoterapia de segunda línea y las guías para el manejo del CRPC metastásico y no metastásico.
CHAARTED
El documento resume los resultados del estudio CHAARTED sobre el uso de docetaxel junto con terapia de deprivación androgénica (ADT) en pacientes con cáncer de próstata hormono-sensible. Los resultados mostraron que la combinación de ADT más docetaxel aumentó significativamente la supervivencia global en comparación con ADT sola para todos los subgrupos, incluidos aquellos con alta carga de enfermedad metastásica al inicio del tratamiento. La conclusión fue que la combinación debería considerarse como tratamiento estándar para estos
Nuevas Prestaciones Oncológicas en el Ges
Este documento resume los cambios recientes en las prestaciones oncológicas cubiertas por el GES. Se amplía la cobertura de cuidados paliativos y se agregan nuevas prestaciones para el cáncer gástrico, de próstata y colorrectal, incluyendo quimioterapias, radioterapias y exámenes específicos. El objetivo es mejorar el acceso a tratamientos integrales contra el cáncer garantizados por el sistema de salud chileno.
Vih y pulmón
El documento describe las complicaciones pulmonares en pacientes con VIH/SIDA. Las vías respiratorias son el sitio más comúnmente afectado, con neumonía bacteriana e infección por Pneumocystis jirovecii siendo las causas más frecuentes. El tratamiento antirretroviral redujo la incidencia de infecciones oportunistas pero aumentó la aparición de otras enfermedades pulmonares no relacionadas al VIH.
Hepatitis Viral
Este documento resume las principales características de las hepatitis virales A, B, C, D y E. Describe la etiología, transmisión, síntomas, diagnóstico, pronóstico y tratamiento de cada tipo de hepatitis viral. Explica que son trastornos hepáticos causados por diferentes virus que provocan inflamación del hígado, y que su presentación clínica puede variar desde asintomática hasta fulminante dependiendo del virus involucrado.
Síndrome Superposición Overlap Hepatitis Autoinmune/Cirrosis Biliar Primaria
1) El síndrome de solapamiento (overlap) se refiere a cuando una persona tiene dos enfermedades hepáticas distintas, como cirrosis biliar primaria (CBP) e hepatitis autoinmune (HAI), de manera simultánea o secuencial.
2) El diagnóstico se puede realizar utilizando los criterios de París y diferenciándolo de una hepatitis inducida por medicamentos.
3) El tratamiento depende de la enfermedad predominante y puede incluir ácido ursodesoxicólico y corticoides.
Inhaladores ASMA EPOC COPD LCFA
Este documento resume los principales tipos de medicamentos utilizados en la terapia inhalatoria para el asma y la EPOC, incluyendo broncodilatadores como los agonistas beta-adrenérgicos de acción corta y prolongada, los anticolinérgicos de acción corta y prolongada, y los antiinflamatorios como los corticoides. Describe los mecanismos de acción, efectos, dosis y formas de administración de estos fármacos, así como sus posibles efectos adversos y el uso de combinaciones de medicamentos.
Ca. pulmonar avanzado etapa III
Este documento resume las guías de tratamiento para el cáncer de pulmón de células no pequeñas en etapa III. Describe los tratamientos estándar para las subetapas IIIA y IIIB, incluida la quimiorradioterapia concurrente para los pacientes irresecables. También discute el papel de la cirugía, la neoadyuvancia y la consolidación en el tratamiento de la etapa IIIA.
Linfoma de Hodgkin
Este documento presenta el caso clínico de una mujer de 36 años diagnosticada con linfoma de Hodgkin etapa IIB. Tuvo adenopatías cervicales, axilares y mediastínicas, así como fatiga, diaforesis y leucocitosis. Se realizó tratamiento con quimioterapia ABVD que llevó a remisión completa luego de 6 ciclos. El documento también revisa aspectos epidemiológicos, histopatológicos y de tratamiento del linfoma de Hodgkin.
HSA y Terapia Triple H
Este documento discute el HSA y la terapia triple H. Explica que el HSA representa el 5% de los casos de ECV en Chile y tiene una alta tasa de mortalidad y discapacidad. Luego describe la fisiopatología del vasoespasmo cerebral y la terapia triple H, que combina hipertensión, hemodilución e hipervolemia. Sin embargo, concluye que solo se recomienda la hipertensión para tratar el vasoespasmo sintomático, y que la normovolemia es igual de efectiva que la hiperv
sindrome cushing
Este documento resume la definición, epidemiología, causas, fisiopatología, manifestaciones clínicas, diagnóstico y tratamiento del síndrome de Cushing. Define el SC como resultado de la exposición crónica a exceso de glucocorticoides, ya sea por corticosteroides exógenos o una fuente endógena de cortisol. Describe las manifestaciones clínicas, los tests de diagnóstico y los enfoques para establecer la causa subyacente, ya sea adenoma hipofisario, tumor suprarrenal u otra et
Micosis fungoides
Micosis Fungoide es un linfoma no-Hodgkin de células T que afecta la piel. Se manifiesta inicialmente como manchas o parches que pueden transformarse en placas más infiltradas o tumores. El diagnóstico se realiza mediante biopsia cutánea e inmunofenotipado. El tratamiento depende del estadio y puede incluir agentes tópicos, fototerapia o quimioterapia sistémica para casos avanzados.
Enfermedad Celíaca
La enfermedad celíaca es un trastorno autoinmune causado por el gluten en personas genéticamente susceptibles. Se caracteriza por daño en la mucosa intestinal y una amplia gama de síntomas. El único tratamiento es seguir una dieta estricta sin gluten de por vida. Nuevas alternativas terapéuticas como inhibidores de zonulina y enzimas que rompen péptidos de gluten se están investigando.
Rehabilitación Pulmonar en la EPOC
La rehabilitación respiratoria en pacientes con EPOC tiene como objetivo reducir los síntomas, mejorar la capacidad funcional y la calidad de vida. Los programas de rehabilitación respiratoria incluyen educación, entrenamiento físico y apoyo psicosocial durante 6 a 12 semanas y han demostrado mejorar significativamente la disnea, la capacidad de ejercicio y la calidad de vida en pacientes con EPOC. La rehabilitación respiratoria debe ser parte integral del tratamiento de los pacientes con EPOC.
Tiroiditis Autoinmune
La tiroiditis autoinmune es una inflamación crónica de la glándula tiroides causada por una respuesta autoinmune. Es la enfermedad autoinmune y el trastorno endocrino más comunes. Puede causar hipotiroidismo y se asocia con factores como el tabaquismo y los niveles de yodo en la dieta. Los anticuerpos antitiroperoxidasa son un marcador serológico importante para el diagnóstico. La ecografía tiroidea muestra típicamente una reducción de la ecogenicidad. El tratamiento inclu
Viewers also liked (20)
Efecto a largo plazo de reducción de sal sobre Presión Arterial
Efecto a largo plazo de reducción de sal sobre Presión Arterial
Síndrome Superposición Overlap Hepatitis Autoinmune/Cirrosis Biliar Primaria
Síndrome Superposición Overlap Hepatitis Autoinmune/Cirrosis Biliar Primaria
Similar to GETUG-AFU 15
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...European School of Oncology
This document summarizes evidence from clinical trials on systemic treatments for high-risk prostate cancer, including androgen deprivation therapy and chemotherapy. Long-term androgen deprivation therapy for 2-3 years is shown to improve outcomes compared to short-term therapy based on trials. The addition of docetaxel to radiation therapy and androgen deprivation is being investigated in ongoing phase III trials to improve survival for high-risk localized prostate cancer.Hormonal Therapy In Prostate Ca
1. Several randomized controlled trials have consistently shown that the addition of neoadjuvant hormonal therapy (NHT) to external beam radiotherapy (EBRT) improves outcomes for men with intermediate-risk or high-risk localized prostate cancer.
2. The optimal timing and duration of NHT is still unclear, but most evidence suggests that 2-3 months of NHT combined with EBRT is adequate for intermediate-risk patients. Longer adjuvant hormonal therapy may benefit high-risk patients.
3. While the sequence of NHT relative to EBRT may impact outcomes, short-term NHT combined with EBRT appears beneficial overall based on multiple randomized trials.
Neadjuvant Hormonal Therapy
1. Several randomized controlled trials have consistently shown that the addition of neoadjuvant hormonal therapy (NHT) to external beam radiotherapy (EBRT) improves outcomes for men with intermediate-risk or high-risk localized prostate cancer.
2. The optimal timing and duration of NHT is still unclear, but most evidence suggests that 2-3 months of NHT combined with EBRT is adequate for intermediate-risk patients. Longer adjuvant hormonal therapy may benefit high-risk patients.
3. While the sequence of NHT relative to EBRT may impact outcomes, 2-3 months of NHT appears beneficial whether used concurrently with EBRT or as a neoadjuvant.
Prostate cancer nemrock 2015 sanofi
This document summarizes a presentation on tackling prostate cancer and improving treatment outcomes. It discusses that prostate cancer incidence is increasing due to aging and screening. Prostate cancer is the second most common cancer in men and is an androgenic disease related to testosterone and the androgen receptor. The presentation reviews prostate cancer risk stratification and how docetaxel added to androgen deprivation therapy can improve outcomes for metastatic hormone-sensitive prostate cancer based on clinical trial results. It also discusses therapies such as abiraterone that have shown survival benefits for castrate-resistant prostate cancer based on additional clinical trials.
Enzalutamide in prostate cancer
#prostatecancer #prostate #cancer #prostatecancerinindia #prostatecancerindelhi #prostatecancertreatment #maxhospital #maxhospitaldelhi #dralokgupta #cancerspecialist #cancerdoctorindelhi #alokgupta
#immunotherapy
Prostate cancer
This document discusses prostate cancer, including:
1. It is the second most common cancer in men and the second leading cause of cancer death in men. Rates are closely related to age and vary geographically.
2. Treatment depends on risk level, ranging from active surveillance for very low risk to radiation therapy or prostatectomy for low risk to radiation plus long-term androgen deprivation therapy for high risk.
3. For metastatic hormone-sensitive prostate cancer, adding docetaxel chemotherapy to initial androgen deprivation therapy improves progression-free and overall survival compared to androgen deprivation therapy alone.
LHRH agonist vs antagonist in prostate cancer
#prostatecancer #prostate #cancer #prostatecancerinindia #prostatecancerindelhi #prostatecancertreatment #maxhospital #maxhospitaldelhi #dralokgupta #cancerspecialist #cancerdoctorindelhi #alokgupta
#immunotherapy
Radiologieinterventionnellechctdebaere
1) Radiofrequency ablation is recommended as the main ablative therapy for HCC tumors less than 5 cm due to better control of the disease. Ablation and resection may be equivalent for very early and early stage HCC.
2) For HCC less than 5 cm in candidates for surgery, the role of new ablation techniques needs to be defined, tool by tool. Combined treatment (TACE+RF) may help address the difficulty of distant recurrence.
3) DEB-TACE and conventional TACE showed similar efficacy and safety profiles in a randomized controlled trial for intermediate HCC, with less post-procedure pain with DEB-TACE. Optimization of bead size is ongoing.
Management of advanced prostate carcinoma
1) The document discusses management of advanced prostate cancer, focusing on high risk disease. Treatment options for high risk prostate cancer include radiotherapy, androgen deprivation therapy, surgery, or a combination approach.
2) Studies have shown that dose escalated external beam radiotherapy improves outcomes for high risk prostate cancer when combined with androgen deprivation therapy. Moderate hypofractionation is a reasonable alternative to standard fractionation.
3) For high risk disease, long term androgen deprivation therapy of 2 years or more is superior to short term therapy when combined with radiotherapy. However, reducing the duration of long term androgen deprivation may be considered.
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
The document summarizes key information about prostate cancer including incidence, mortality rates, clinical stages, risk groups for localized prostate cancer, treatment options for advanced disease including hormone therapy and chemotherapy, and results from clinical trials of chemotherapy agents like docetaxel and cabazitaxel.Metastatic prostate cancer
This document presents a case scenario for choosing the best management strategy for a 73-year-old male patient with hormone-naïve metastatic prostate cancer. The patient has bone metastases, a PSA of 115 ng/ml, and biopsy-confirmed Grade 4 prostate adenocarcinoma. Treatment options discussed include ADT alone, ADT plus abiraterone, ADT plus docetaxel, and newer approvals like apalutamide and enzalutamide. Key trials comparing these options are summarized. Factors to consider in choosing a treatment include availability, tolerability, differential toxicity profiles, and efficacy based on the patient's individual risk profile. For this patient who has completed ADT plus doc
Cancer prostate
Locally advanced and metastatic prostate cancer can be treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination. For locally advanced disease, short-term and long-term hormone therapy combined with radiation therapy improves outcomes. Adjuvant radiation after prostatectomy improves survival for high-risk patients. Advanced disease is treated by depleting androgens through surgical or medical castration. Newer agents like abiraterone, enzalutamide, radium-223, cabazitaxel, and sipuleucel-T provide additional treatment options.
Prostate cancer : Changing Treatment Paradigm
#prostatecancer #prostate #cancer #prostatecancerinindia #prostatecancerindelhi #prostatecancertreatment #maxhospital #maxhospitaldelhi #dralokgupta #cancerspecialist #cancerdoctorindelhi #alokgupta
#immunotherapy
#medantalucknow
#lucknowcancer
#dralokguptaonco
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent chemoradiation (CT-RT) has been studied as an alternative to primary CT-RT for locally advanced head and neck cancers. Meta-analyses have found induction chemotherapy provides no survival benefit compared to primary CT-RT and is associated with increased toxicity. Recent large randomized trials could not demonstrate an improvement with induction chemotherapy due to inadequate accrual and poor compliance with subsequent CT-RT. While induction chemotherapy may improve organ preservation or outcomes for select subgroups like HPV-negative cancers, current evidence indicates primary CT-RT remains the standard of care for most patients.
Locally Advanced Carcinoma Prostate
Locally advanced Ca prostate
Courtesy : NCCN , Perez, Gunderson and Tepper
Brief outline on management
ADT, Radiotherapy, Surgery indications and Standard of care
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
1) Adding hormone therapy to radiotherapy improves outcomes for prostate cancer, including disease-specific mortality and distant metastases.
2) For high-risk or locally advanced prostate cancer, short-course neoadjuvant hormone therapy of 3-6 months improves local control when combined with radiotherapy.
3) Long-term hormone therapy of at least 2 years reduces the risk of metastases and improves survival more than short-term therapy, especially for high-grade disease.
Quimioterapia en cáncer de próstata
The document discusses several clinical trials evaluating the role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). The CHAARTED trial found that for patients with high-volume mCRPC, the addition of docetaxel to androgen deprivation therapy (ADT) improved overall survival by 13.3 months compared to ADT alone. The STAMPEDE trial also found a survival benefit to adding docetaxel or zoledronic acid to standard of care. The GETUG-15 trial demonstrated a survival benefit for patients with high-volume disease receiving early docetaxel and ADT compared to ADT alone. Together these trials provide evidence supporting the use of docetaxel chemotherapy
LN management in ASIA Chan TM.pdf
This document summarizes research on the management of lupus nephritis in Asia. It finds that the prevalence and severity of lupus nephritis varies significantly across Asia. Initial treatment typically involves corticosteroids combined with cyclophosphamide or mycophenolate mofetil. Achieving remission is important for long-term renal and patient survival. Studies comparing cyclophosphamide and mycophenolate mofetil found similar response rates but mycophenolate mofetil had fewer adverse effects. For maintenance treatment, mycophenolate mofetil appears superior to azathioprine in preventing flares. Treatment approaches may need to consider ethnic and regional factors in Asia.
2015 ASCO Genitourinary Cancers Update
2015 ASCO Genitourinary Cancers Update
June 13, 2015
Amir Mortazavi, MD
Clinical Assistant Professor of Internal Medicine
CCO_Prostate_Cancer_Advances_Downloadable_3.pptx
Systemic Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Three clinical trials showed that adding docetaxel or abiraterone to androgen deprivation therapy (ADT) improved overall survival for men with metastatic hormone-sensitive prostate cancer compared to ADT alone. Additional trials found that apalutamide, enzalutamide, and darolutamide combined with ADT extended progression-free survival and time to pain progression or skeletal-related events compared to placebo plus ADT. The benefit of adding these novel hormonal agents or docetaxel to initial ADT was greater for men with high-volume versus low-volume disease.
Similar to GETUG-AFU 15 (20)
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
More from UACH, Valdivia
Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone t...
Antiemetic Corticosteroid Rotation from Dexamethasone to
Methylprednisolone to Prevent Dexamethasone-Induced
Hiccup in Cancer Patients Treated with Chemotherapy:
A Randomized, Single-Blind, Crossover Phase III Trial
Fentanylo oral en Profilaxis Disnea Esfuerzo
Este estudio piloto evaluó el efecto del fentanilo bucal en la disnea de esfuerzo en pacientes con cáncer. El estudio asignó aleatoriamente 22 pacientes a recibir fentanilo bucal o placebo antes de una caminata de 6 minutos. Los pacientes que recibieron fentanilo reportaron una mejoría significativamente mayor en la intensidad de la disnea al final de la caminata en comparación con su línea de base. Aunque la mejoría fue mayor en el grupo de fentanilo, la diferencia entre los grupos no fue estadísticamente signific
Ca. gastrico 2ª Lineas
This document summarizes a clinical case of a 42-year-old male diagnosed with stage IV gastric cancer. He initially presented with abdominal pain and weight loss and was found to have an ulcerated, poorly differentiated adenocarcinoma. Despite an initial partial response to first-line chemotherapy with CapeOx plus trastuzumab, his cancer progressed in the liver and peritoneum. He was then treated with ramucirumab and FOLFIRI chemotherapy, representing a second-line treatment option discussed at this clinical meeting.
Cáncer Recto
Este documento resume la evolución del tratamiento del cáncer rectal, desde la cirugía como único tratamiento hasta la incorporación de la radioterapia y quimioterapia adyuvante o neoadyuvante. Estudios clave mostraron que la radioterapia preoperatoria reduce la tasa de recidivas locales y mejora los resultados quirúrgicos. Más recientemente, ensayos añadieron quimioterapia neoadyuvante con esquemas como FOLFOX, mostrando mayores tasas de downstaging tumoral y supervivencia, con
Proportion of second cancers attributable to radiotherapy treatment in adults...
Este estudio encontró que la radioterapia aumenta el riesgo de desarrollar un segundo cáncer sólido. El riesgo relativo varió de 1.08 para cáncer de ojo a 1.43 para cáncer testicular. Se estimó que el 8% de los segundos cánceres podrían estar relacionados con la radioterapia, lo que equivale a 5 casos por cada 1000 pacientes tratados con radioterapia 15 años después del diagnóstico original. La quimioterapia también aumenta el riesgo de leucemia, y los agentes al
Optimal fractionation of preoperative radiotherapy and timing to surgery for ...
Este estudio comparó tres brazos de tratamiento para cáncer rectal: radioterapia de dosis corta seguida de cirugía inmediata, radioterapia de dosis corta seguida de cirugía después de 4-8 semanas, y radioterapia de dosis larga seguida de cirugía después de 4-8 semanas. Los resultados mostraron que la radioterapia de dosis corta con cirugía diferida es una alternativa viable a la radioterapia de dosis corta con cirugía inmediata, con menos complicaciones posteriores a
Cáncer páncreas 2017
- The document discusses pancreatic cancer epidemiology and molecular biology. Some key points:
- Worldwide, pancreatic cancer incidence is about 8 per 100,000 and mortality is 7-8 per 100,000, making it the 8th most common cancer.
- In Chile, incidence and mortality are slightly higher than worldwide averages.
- About 60% of pancreatic cancers are metastatic at diagnosis, 30% are locally advanced, and only 10% are early-stage.
- KRAS mutations are present in approximately 95% of pancreatic cancers.
Cáncer Mama Ultimos Trabajos Septiembre 2017
El documento presenta resúmenes de varios estudios clínicos sobre el tratamiento del cáncer de mama. MONARCH 2 encontró que abemaciclib más fulvestrant mejoró la supervivencia libre de progresión en comparación con placebo más fulvestrant en pacientes con cáncer de mama avanzado RH+/HER2-. I-SPY 2 predijo una mayor probabilidad de éxito para pembrolizumab más paclitaxel que paclitaxel solo en neoadyuvante. PlanB encontró que docetaxel más ciclofosfamida no
Estudio Fase ii 2017
Este estudio fase II evaluó la eficacia y seguridad de la combinación de nab-paclitaxel, carboplatino y bevacizumab como tratamiento de primera línea en 50 pacientes con cáncer de pulmón no microcítico avanzado. Los resultados mostraron una tasa de respuesta global del 31.3% y una enfermedad estable en el 54.2% de los pacientes. La toxicidad hematológica más común fue neutropenia, pero fue manejable. Los resultados preliminares indican que esta combinación tiene actividad prometedora
Biopsia líquida
Este documento describe la biopsia líquida como una técnica minimamente invasiva para detectar biomarcadores en fluidos corporales como sangre y orina. La biopsia líquida puede aislar ADN tumoral circulante, células tumorales circulantes y exosomas que contienen material genético del tumor. Aunque es una alternativa prometedora a la biopsia tumoral, la biopsia líquida tiene limitaciones como baja sensibilidad. El documento concluye que la biopsia líquida es una segunda opción para detectar mutaciones en EGFR, pero
Lung Cancer T790M Novo
Este resumen describe el caso de un hombre de 63 años diagnosticado con adenocarcinoma pulmonar con mutación EGFR T790M. Recibió tratamiento con pemetrexato-carboplatino con una respuesta parcial. Se discute que la mutación T790M es poco frecuente y causa resistencia a TKI de primera generación. Los estudios muestran que la tercera generación de TKI puede ser efectiva en estos casos.
Ca. Pulmonar 2017
Dacomitinib demostró ser superior a gefitinib como tratamiento de primera línea para cáncer de pulmón no microcítico avanzado con mutación EGFR. La mediana de supervivencia libre de progresión fue más larga con dacomitinib que con gefitinib (14.7 meses vs 9.2 meses). Además, la tasa de respuesta general fue mayor con dacomitinib. Los efectos adversos graves fueron similares entre los dos brazos.
Timoma, Thymoma or Thymic carcinoma
Este documento presenta el caso clínico de una paciente de 53 años con timoma tipo B3 resecado en 2011 que ha presentado progresión pulmonar y pleural. Se describen los antecedentes personales y familiares de la paciente, los resultados de las imágenes y biopsias realizadas, y los diagnósticos establecidos. Adicionalmente, se incluye una revisión sobre timoma que resume aspectos clínicos, histológicos, de estadificación y tratamiento del tumor, incluyendo diferentes esquemas de quimioterapia evalu
Cáncer Hipofaringe
El documento presenta el caso clínico de un paciente de 72 años diagnosticado con carcinoma de hipofaringe. Tuvo antecedentes de cáncer de cavidad oral sincrónico. Se realizaron exámenes como tomografía, endoscopia y biopsia que confirmaron el diagnóstico. El tratamiento óptimo para este tipo de cáncer en etapas avanzadas es la quimiorradioterapia concurrente, la cual ha demostrado mejorar los resultados en comparación a la cirugía o radioterapia sola. La radioterapia fraccionada alterada también puede
Cáncer de cabeza y cuello
Estos estudios muestran los beneficios de la quimiorradioterapia concurrente frente a la radioterapia sola en el tratamiento del cáncer de cabeza y cuello localmente avanzado, incluyendo mejor sobrevida libre de progresión, sobrevida global y control local. Aunque dos ciclos de quimioterapia concurrente con cisplatino parecen ser suficientes, un ciclo solo es inferior. La quimiorradioterapia también permite la preservación de órganos funcionales como la laringe.
Cancer Mama Triple Negativo
Este documento describe el cáncer de mama triple negativo, incluyendo sus características clínico-patológicas, factores de riesgo, subtipos histológicos y moleculares, y opciones de tratamiento. El cáncer de mama triple negativo se caracteriza por ser negativo para los receptores de estrógeno, progesterona y HER2. Los factores de riesgo incluyen edad menor de 40 años, raza negra o hispana, y mutaciones en el gen BRCA1. Las opciones de tratamiento incluyen quimioter
Ca. pulmonar metastasico
El documento presenta el caso clínico de un paciente de 68 años diagnosticado con cáncer pulmonar no microcélular metastásico en etapa IV. Describe las opciones de tratamiento de primera línea incluyendo quimioterapia basada en platino, inhibidores de EGFR para pacientes con mutación EGFR, y tratamiento de mantenimiento con pemetrexed. También discute factores como la histología, comorbilidades y estado funcional al decidir el tratamiento más adecuado.
CPCP
El documento presenta el caso clínico de un paciente de 66 años diagnosticado con cáncer de pulmón de células pequeñas en etapa IV. Recibió 6 ciclos de quimioterapia con cisplatino y etopósido como primera línea, sin toxicidad. Tras progresión cerebral recibió radioterapia y se presenta para iniciar paclitaxel semanal como segunda línea. El cáncer de células pequeñas tiene mal pronóstico a pesar de los avances, siendo necesaria más investigación sobre nuevas dianas terap
Cancer Renal Metastasico Tumor Growth Rate
Este documento presenta el uso potencial del Tumor Growth Rate (TGR) o tasa de crecimiento tumoral para guiar la terapia de segunda línea en pacientes con cáncer renal metastásico. El TGR mide el cambio en el volumen tumoral con el tiempo y podría usarse junto con el juicio clínico para decidir entre opciones de tratamiento como nivolumab, cabozantinib o axitinib dependiendo si el TGR es alto, bajo o intermedio. El autor concluye que el TGR podría ser una herramienta útil para evaluar
Ca. gástrico metastásico inmunoterapia
The document describes a case study of a 72-year-old male patient with metastatic gastric cancer who showed a partial response after 20 months of treatment with pembrolizumab immunotherapy, with reduction in tumor size of multiple lesions of over 70%. It then reviews the KEYNOTE-012 trial which found that pembrolizumab achieved an objective response rate of 33% in patients with advanced gastric cancer. Ongoing trials are investigating nivolumab as a potential treatment for gastric cancer patients who have progressed on two or more prior chemotherapy regimens.
More from UACH, Valdivia (20)
Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone t...
Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone t...
Proportion of second cancers attributable to radiotherapy treatment in adults...
Proportion of second cancers attributable to radiotherapy treatment in adults...
Optimal fractionation of preoperative radiotherapy and timing to surgery for ...
Optimal fractionation of preoperative radiotherapy and timing to surgery for ...
Recently uploaded
mortality & morbidity indicators of health .pptx
Indicators for measurement of health including mortality, morbidity an d disability
Allopurinol (Anti-gout drug).pptx
Allopurinol, a uric acid synthesis inhibitor acts by inhibiting Xanthine oxidase competitively as well as non- competitively, Whereas Oxypurinol is a non-competitive inhibitor of xanthine oxidase.
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Skin is the largest organ of the human body, serving crucial functions that include protection, sensation, regulation, and synthesis. Structurally, it consists of three main layers: the epidermis, dermis, and hypodermis (subcutaneous layer).
1. **Epidermis**: The outermost layer primarily composed of epithelial cells called keratinocytes. It provides a protective barrier against environmental factors, pathogens, and UV radiation.
2. **Dermis**: Located beneath the epidermis, the dermis contains connective tissue, blood vessels, hair follicles, and sweat glands. It plays a vital role in supporting and nourishing the epidermis, regulating body temperature, and housing sensory receptors for touch, pressure, temperature, and pain.
3. **Hypodermis**: Also known as the subcutaneous layer, it consists of fat and connective tissue that anchors the skin to underlying structures like muscles and bones. It provides insulation, cushioning, and energy storage.
Skin performs essential functions such as regulating body temperature through sweat production and blood flow control, synthesizing vitamin D when exposed to sunlight, and serving as a sensory interface with the external environment.
Maintaining skin health is crucial for overall well-being, involving proper hygiene, hydration, protection from sun exposure, and avoiding harmful substances. Skin conditions and diseases range from minor irritations to chronic disorders, emphasizing the importance of regular care and medical attention when needed.
Selective α1-Blocker.pptx
Selective alpha1 blockers are Prazosin, Terazosin, Doxazosin, Tamsulosin and Silodosin majorly used to treat BPH, also hypertension, PTSD, Raynaud's phenomenon, CHF
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Wabsite For Rant : babesbookhot@gmail.com
ℂall Girls 𝕀ndore ( 000000000 ) 𝕍𝕚𝕡 ℂall girl Indore
ℂall Girls 𝕀ndore ( 000000000 ) 𝕍𝕚𝕡 ℂall girl Indore
5 Effective Homeopathic Medicines for Irregular Periods
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...PVI, PeerView Institute for Medical Education
Milan J. Anadkat, MD, and Dale V. Reisner discuss generalized pustular psoriasis in this CME activity titled "Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making." For the full presentation, please visit us at www.peervoice.com/HUM870.Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Acne is a common skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It typically manifests as pimples, blackheads, or whiteheads, often on the face, chest, shoulders, or back. Acne can range from mild to severe and may cause emotional distress and scarring in some cases.
**Causes:**
1. **Excess Oil Production:** Hormonal changes during adolescence or certain times in adulthood can increase sebum (oil) production, leading to clogged pores.
2. **Clogged Pores:** When dead skin cells and oil block hair follicles, bacteria (usually Propionibacterium acnes) can thrive, causing inflammation and acne lesions.
3. **Hormonal Factors:** Fluctuations in hormone levels, such as during puberty, menstrual cycles, pregnancy, or certain medical conditions, can contribute to acne.
4. **Genetics:** A family history of acne can increase the likelihood of developing the condition.
**Types of Acne:**
- **Whiteheads:** Closed plugged pores.
- **Blackheads:** Open plugged pores with a dark surface.
- **Papules:** Small red, tender bumps.
- **Pustules:** Pimples with pus at their tips.
- **Nodules:** Large, solid, painful lumps beneath the surface.
- **Cysts:** Painful, pus-filled lumps beneath the surface that can cause scarring.
**Treatment:**
Treatment depends on the severity and type of acne but may include:
- **Topical Treatments:** Such as benzoyl peroxide, salicylic acid, or retinoids to reduce bacteria and unclog pores.
- **Oral Medications:** Antibiotics or oral contraceptives for hormonal acne.
- **Procedures:** Such as chemical peels, extraction of comedones, or light therapy for more severe cases.
**Prevention and Management:**
- **Cleanse:** Regularly wash skin with a gentle cleanser.
- **Moisturize:** Use non-comedogenic moisturizers to keep skin hydrated without clogging pores.
- **Avoid Irritants:** Such as harsh cosmetics or excessive scrubbing.
- **Sun Protection:** Use sunscreen to prevent exacerbation of acne scars and inflammation.
Acne treatment can take time, and consistency in skincare routines and treatments is crucial. Consulting a dermatologist can help tailor a treatment plan that suits individual needs and reduces the risk of scarring or long-term skin damage.
All about shoulder Joint ..
All about shoulder joint , Anatomy ,Examination, Special tests and radiology.
Digital Smile Design-An innovative tool in aesthetic dentistry.pptx
Digital Smile Design-An innovative tool in aesthetic dentistry.pptxDigital Smile Design-An innovative tool in aesthetic dentistry.pptxDigital Smile Design-An innovative tool in aesthetic dentistry.pptxDigital Smile Design-An innovative tool in aesthetic dentistry.pptxDigital Smile Design-An innovative tool in aesthetic dentistry.pptxDigital Smile Design-An innovative tool in aesthetic dentistry.pptxDigital Smile Design-An innovative tool in aesthetic dentistry.pptxv
Public Health Lecture 4 Social Sciences and Public Health
Sociology, Anthropology and Psychology as applied to Public Health
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Service Available
Nano-gold for Cancer Therapy chemistry investigatory project
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Pharmacology of Drugs for Congestive Heart Failure
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
Helminthiasis or Worm infestation in Children for Nursing students
Brief description worm infestation/Helminthiasis for Basic B.Sc Nursing students
Recently uploaded (20)
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
ℂall Girls 𝕀ndore ( 000000000 ) 𝕍𝕚𝕡 ℂall girl Indore
ℂall Girls 𝕀ndore ( 000000000 ) 𝕍𝕚𝕡 ℂall girl Indore
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Digital Smile Design-An innovative tool in aesthetic dentistry.pptx
Digital Smile Design-An innovative tool in aesthetic dentistry.pptx
Public Health Lecture 4 Social Sciences and Public Health
Public Health Lecture 4 Social Sciences and Public Health
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
Pharmacology of Drugs for Congestive Heart Failure
Pharmacology of Drugs for Congestive Heart Failure
Helminthiasis or Worm infestation in Children for Nursing students
Helminthiasis or Worm infestation in Children for Nursing students
GETUG-AFU 15
- 1. GETUG – AFU 15 Dr. Daniel Agüero Velásquez Residente Oncología Médica 2016
- 2. The Hypothesis • Docetaxel added at the time of starting ADT in hormone-sensitive metastatic prostate cancer (mHSPC) will prolong overall survival (OS)
- 3. Metastatic HSPC: GETUG 15 Trial Design n = 385 pts 2 ADT: - LHRH agonist - or maximum androgen blockade - or orchiectomy 3 75 mg/m2 q3 up to 9 cycles Gravis G, et al. Lancet Oncol. 2013;14(2):149-158. 1 Glass TR, et al. J Urol. 2003;169(1):164-169.
- 4. Median PFS: ADT + D: 23 mo [19.6-28.4] ADT: 13 mo [11.9-17.7] HR [95%CI]: 0.72 [0.57-0.91] P = .0052 ADT+ docetaxel ADT ADT ADT+ docetaxel Gravis G, et al. Lancet Oncol. 2013;14(2):149-158. Biochemical Progression-Free Survival:
- 5. Median cPFS: ADT + D: 23 mo [20.5-32] ADT: 15 mo [12.5-20] HR [95%CI]: 0.75 [0.59-0.94] P = .0147 ADT+ docetaxel ADT Clinical Progression-Free Survival: ADT ADT+ docetaxel Gravis G, et al. Lancet Oncol. 2013;14(2):149-158.
- 6. Median OS: ADT + D: 59 mo [51-69] ADT: 54 mo [42-NR] HR [95%CI]: 1.01 [0.75-1.36] P = .95 ADT + docetaxel ADT ADT ADT + docetaxel Median follow-up: 50 months [49 - 54] Overall Survival Gravis G, et al. Lancet Oncol. 2013;14(2):149-158.